Kybella and Belkyra are essentially the same product used for fat dissolving treatments, with the primary difference being their branding in different regions. Both utilise deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat, to target and eliminate fat cells in specific areas, particularly under the chin. This process results in a noticeable reduction of fullness in the treated area, providing a more contoured appearance.
Understanding Kybella
Kybella is the brand name used in the United States for this injectable treatment. It is approved by the U.S. Food and Drug Administration (FDA) for adults with moderate to severe fat below the chin, known as submental fat. Kybella is specifically designed to improve the appearance and profile of patients who feel self-conscious about their double chin. The treatment involves a series of injections, with the number of sessions varying based on the individual’s aesthetic goals and the amount of submental fat.
Diving into Belkyra
Belkyra, on the other hand, is the name given to this fat-dissolving treatment in countries like Canada and Australia. The formulation and application are identical to Kybella, as both utilise the same active ingredient, deoxycholic acid. The main distinction lies in the regulatory approvals and branding tailored to different markets. Just like Kybella, Belkyra is administered through injections directly into the submental area. Patients typically require multiple sessions to achieve their desired results, with the treatment plan tailored to individual needs.
Key Considerations for Practitioners
For practitioners, the choice between Kybella and Belkyra depends largely on the geographical location and regulatory guidelines of the country in which they practice. It is crucial to ensure that the treatment is administered by a trained professional to minimise risks and enhance patient outcomes. Both products have undergone rigorous clinical testing to ensure their safety and efficacy. Patients should be informed about the potential side effects, such as swelling, bruising, or numbness, which are typically temporary. By understanding the nuances of these treatments, practitioners can offer informed recommendations to clients seeking to address submental fullness.
The primary difference between Kybella and Belkyra is their branding, dictated by the region in which they are marketed. Kybella is the name used in the United States, while Belkyra is used in Canada, Australia, and some European countries. Both products are identical in formulation and usage, containing deoxycholic acid to dissolve fat cells.
In terms of application, both Kybella and Belkyra require a series of injections to achieve the desired reduction in submental fat. The number of sessions varies based on individual goals and the initial amount of fat. The process is minimally invasive, offering an alternative to surgical options like liposuction.
Ultimately, the choice between Kybella and Belkyra hinges on location and regulatory approvals. Practitioners should ensure they are using the correct product for their region and be well-versed in its administration to provide optimal results for their clients.
